Skip to main content

Table 6 All-cause ESKD-associated variants at P < 5 × 10−6 in APOL1-negative model

From: Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

Lead variant

CHR

POS

Locus

Effect/other allele

*Info

Stage 2: Meta-analysis (2768 T2D-ESKD cases vs. 6059 non-diabetic non-nephropathy controls)

Stage 4 (1019 non-diabetic ESKD cases vs. 733 non-diabetic non-nephropathy controls)

Stage 5 (3787 all-cause ESKD cases vs. 6059 non-diabetic non-nephropathy controls)

EAF

OR (95% CI)

P

EAF

OR(95% CI)

P

EAF

OR (95% CI)

P

HetP

rs12472637

2

30304514

ALK/YPEL5

A/G

0.94

0.33

0.81 (0.74, 0.89)

6.05E−06

0.36

0.8 (0.66, 0.96)

0.019

0.33

0.82 (0.76, 0.89)

4.47E−06

0.83

rs76971802

3

188607071

LPP

T/C

0.95

0.09

1.43 (1.24, 1.65)

1.06E−06

0.08

1.45 (1.03, 2.05)

0.032

0.088

1.42 (1.24, 1.62)

5.76E−07

0.93

rs6459733

7

156930550

MNX1-AS1/UBE3C

G/C

0.97

0.39

1.25 (1.15, 0.87)

1.32E−07

0.39

1.25 (1.03, 1.53)

0.026

0.39

1.24 (1.15, 1.35)

7.17E−08

0.83

rs4910809

11

3813850

NUP98

C/G

0.98

0.02

0.53 (0.4, 0.7)

9.46E−06

0.02

0.53 (0.29, 0.95)

0.034

0.023

0.53 (0.41, 0.69)

2.12E−06

0.63

rs219020

13

63013622

LINC01075/LINC00448

C/T

0.97

0.14

1.31 (1.17, 0.86)

6.84E−06

0.11

1.38 (1.02, 1.87)

0.037

0.14

1.31 (1.17, 1.47)

2.12E−06

0.58

rs113452507

15

37954309

TMCO5A

C/G

0.92

0.16

1.29 (1.15, 1.45)

9.71E−06

0.16

1.38 (1.07, 1.77)

0.014

0.16

1.31 (1.18, 1.45)

8.48E−07

0.93

rs373971520

19

2568805

GNG7

–/CA

0.81

0.11

1.47 (1.28, 1.7)

8.97E−08

0.11

1.39 (1.01, 1.91)

0.044

0.11

1.46 (1.28, 1.67)

2.17E−08

0.016

rs6094913

20

46561443

SULF2/LINC01522

G/A

0.93

0.09

0.72 (0.63, 1.6)

8.28E−06

0.10

0.67 (0.48, 0.91)

0.012

0.092

0.72 (0.63, 0.83)

2.5E−06

0.70

  1. Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, CHR chromosome, POS position, EAF effect allele frequency, OR odds ratio, CI confidence interval, P P value, *Info imputation quality, HetP heterogeneity P value;
  2. APOL1-negative model: adjusted for age, sex, and PC1; APOL1 risk genotype carriers were excluded